[바이오사 리포트] 소마젠, 본업 BEP 접근…변수는 일본 DTC 손실

SomaGen posted record Q1 revenue ($8.76M) with 61% operating loss reduction, approaching break-even on core business. However, Japan's DTC division reported 42% higher losses despite 14.8% revenue growth, offsetting consolidated profitability gains. Full-year profitability hinges on reducing Japan losses and accelerating emerging services (single-cell, proteomics) while stabilizing the NGS segment.